BioArctic After Q2 2026: A Royalty Engine That Needs Leqembi to Hit ¥38 Billion a Quarter

On the surface, BioArctic AB's second-quarter report, published August 26, looked like bad news. Net revenue fell to SEK 247.5 million from SEK 392.1 million a year earlier, and the company swung from a SEK 179.1 million operating profit to a SEK 6.5 million operating loss. The shares dropped about 5% — the US-listed ticker, BRCTF, traded down to roughly $327 — and a quick glance at the headline invites the obvious read: shrinking revenue, negative earnings, get out.

The decline has a one-word explanation, and it is timing, not business decay. Roughly SEK 223 million of the year-ago quarter was a one-off milestone payment that had no echo this year. Strip it out and the recurring machinery grew: royalty income from Leqembi rose to SEK 179.4 million from SEK 162.5 million. The first lesson in reading this company is that its income statement is not the number to watch. BioArctic is not a drugmaker in the normal sense. It is a royalty collector on one product — lecanemab, sold as Leqembi — that Eisai, with Biogen, develops, manufactures, prices, and markets. BioArctic earns a percentage of global net sales, layered milestone payments, and a modest co-promotion arrangement in its home region. Apply the company's own two disclosed numbers to each other and the royalty line runs just over a tenth of Leqembi's sales: SEK 179.4 million in the quarter against ¥29.3 billion, roughly SEK 1.7 billion at the conversion rates used in this very report.

That structure is the whole investment debate in miniature. BioArctic does not control its own revenue; it is a leveraged claim on another company's ability to sell one drug.

Which brings in the second number, the one that actually sets the stock's value. Eisai is guiding to ¥143.5 billion of Leqembi sales — about SEK 8.4 billion, roughly $900 million — for its fiscal year running April 2026 through March 2027, a 63% jump over the ¥88 billion the drug sold in the just-completed year. At the same ~10% ratio, that forecast works out to roughly SEK 880 million of royalty income for BioArctic in the year, nearly double the SEK 502.6 million it booked across all of calendar 2025.

Now do the arithmetic the guidance obliges you to. The first quarter of Eisai's fiscal year, April through June, produced ¥29.3 billion of Leqembi sales — up 27% from the ¥23.1 billion a year earlier. The three quarters still to come must therefore deliver ¥114 billion, an average of just over ¥38 billion a quarter. That is about 30% above the run rate just reported, and roughly 75% higher than the same three quarters last year. In plain English: the entire 63% growth year is still ahead of the data, not behind it.

The near-term catalysts are real, which is why the bet is not crazy. The FDA approved the subcutaneous version, Leqembi Iqlik, in July, and Eisai launched the at-home injection for treatment initiation in the US in late August — the most important access unlocker to date, because the infusion-clinic bottleneck has been a standing constraint. China produced about $30 million of sales in the quarter and has the autoinjector under priority review. Japan, where sales slipped on an infusion-capacity squeeze, has an autoinjector decision expected in the current quarter. The honest counterweight is history. Eisai has trimmed Leqembi's outlook repeatedly — its fiscal 2024 target was cut to ¥42.5 billion from ¥56.5 billion — before it finally over-delivered, beating its own guidance with ¥88 billion of actual sales. The report card is genuinely improving; a fresh quarterly sales print is simply the checkpoint on whether the improvement is compounding as fast as the new target demands.

Valuation is where the market states its answer. Around SEK 330, BioArctic carries a market value of roughly SEK 30 billion — about $2.9 billion — against cash of roughly SEK 2 billion. That is about 34 times the SEK 880 million of royalty this year's forecast implies, a multiple that assumes sustained compounding, not a plateau. Push growth forward another 30% into fiscal 2027 and the multiple only falls to the high 20s — still a growth price on a royalty stream whose underlying product has room to disappoint. The sell-side has yet to reach a meeting of minds, which is itself a signal: Buy ratings with targets as high as SEK 363 from DNB, a Neutral from Goldman Sachs at SEK 339, a long-standing Sell from Nordea near SEK 240, and an average published target around SEK 317 that sits below where the shares have actually traded this week.

That disagreement is the correct response to the structure, not a failure of analysis. The stock is a single-product, partner-controlled bet whose value turns on one number issued by someone else. In a portfolio it belongs at the aggressive end of a barbell — a satellite holding, sized so that a 30–40% drawdown, the kind a royalty claim on an unproven forecast can produce, does not rearrange your plan. It hedges nothing; it concentrates risk by design, which is exactly why it should sit beside income and durable cash-flow names rather than inside them.

So ignore BioArctic's own income statement and track the number that actually drives it: Leqembi's quarterly sales against the ¥38 billion-a-quarter bar embedded in the forecast. Eisai prints that figure four times a year, and it is the earliest honest signal of whether the royalty engine is compounding or stalling. If the next quarter lands at ¥35–40 billion, the story is working and the 34-times multiple starts to compress quickly. If it prints ¥30 billion again, you have your answer months before BioArctic's own financials will spell it out. That is the discipline of a single-name royalty story: you do not need to predict the future, only to track the one number the future already depends on.